FSFI endpoint comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
Early work on melanocortin analogs in the 1980s and 1990s produced peptides intended to influence pigmentation and appetite. One of these, melanotan II, was observed to affect sexual desire as an incidental finding in self-administration reports. Researchers then pursued analogs with altered receptor selectivity and improved handling characteristics, and PT-141 emerged from that program in the late 1990s. The development path moved from dermatology and metabolism toward a central nervous system application, a shift that shaped both trial designs and the eventual label.
Regulatory review of bremelanotide concluded in 2019 with approval in the United States for a defined indication in premenopausal women. The reviewed formulation is a single-use prefilled autoinjector given subcutaneously, and its label carries cardiovascular monitoring language tied to blood pressure changes recorded during trials. Availability outside the approving jurisdiction varies, and in several countries the compound remains unapproved or is handled as a prescription-only item. Compounded and research-grade material also circulates, and it differs from the reviewed product in purity, characterization, and chain of custody.
Bremelanotide is a cyclic heptapeptide that acts as an agonist at melanocortin receptors. It binds MC1R, MC3R, MC4R, and MC5R, with MC4R activation considered most relevant to sexual desire pathways in the central nervous system. The molecule is a synthetic analog of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation and energy regulation. Early research explored its use in tanning before attention shifted toward sexual dysfunction applications. Receptor binding affinity varies across these subtypes.
Activation of MC4R in the hypothalamus is thought to influence dopaminergic signaling, which in turn affects arousal and desire. This mechanism differs from that of phosphodiesterase type 5 inhibitors, which act primarily on vascular smooth muscle in the genital region. Because the pathway is central rather than peripheral, effects are not strictly dependent on local blood flow. The precise downstream cascade linking receptor binding to behavioral outcomes remains an area of ongoing investigation.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C50H68N14O10 | Cyclic heptapeptide core |
| Molecular weight | 1025.2 g/mol | Calculated for the free base |
| CAS registry number | 189691-06-3 | Free base; the acetate salt has a separate entry |
| Solubility class | Water-soluble | Freely soluble in aqueous media near neutral pH |
| Typical storage | 2 to 8 °C | Protect from light; avoid repeated freeze-thaw cycles |
Compared with the related compound melanotan II, PT-141 shows markedly weaker activation of receptors tied to pigmentation. This difference stems from subtle structural variations that alter affinity distribution across receptor subtypes. Investigators propose that such selectivity produces a different side effect profile in specific applications. However, downstream consequences of prolonged receptor activation remain uncertain in the literature. Published studies do not fully agree on the duration of signaling pathway activity and the mechanisms of desensitization.
From a pharmacokinetic standpoint, the peptide is usually delivered by injection because oral bioavailability is very low; proteases in the digestive tract degrade it rapidly. After subcutaneous administration, plasma concentrations reach a peak within roughly one hour. Its elimination half-life is relatively short, with most reports placing it in the range of a few hours. Nasal formulations have also been examined, though absorption varies widely between individuals. Metabolism proceeds mainly through peptidase cleavage, and the resulting products are excreted by the kidneys.
PT-141 initiates cellular signaling by binding to specific subtypes within the melanocortin receptor family. These receptors belong to the G protein-coupled receptor superfamily, and activation raises intracellular cyclic adenosine monophosphate levels. This cascade ultimately influences neuronal circuits in the central nervous system that are associated with sexual desire and arousal. Research indicates the compound's action concentrates in hypothalamic regions rather than peripheral tissues, which helps explain some observed pharmacological features. The selectivity of receptor binding underlies its functional differences.
Regulatory status varies by jurisdiction, where approved prescription products, compounded preparations and research-grade material are treated as distinct categories with different documentation requirements. Suppliers of research material commonly issue a certificate of analysis listing purity, identity and sometimes endotoxin content. Independent verification by a third-party laboratory is often recommended because self-reported figures are difficult to check. Literature discussions usually state the source, purity and storage conditions of the material used, since these details affect reproducibility. Analysts note that a reported purity figure does not by itself describe biological activity.
Lyophilised peptide is generally held below minus twenty degrees Celsius, protected from light and moisture, because hydrolysis and oxidation accumulate faster at ambient temperature. Once reconstituted, solutions are typically kept between two and eight degrees Celsius and used within a short window defined by the supplier. Repeated freeze-thaw cycles are avoided since they promote aggregation and loss of soluble material. Container material matters as well, because peptides adsorb to certain plastics and glass surfaces at low concentration. Stability figures supplied by a vendor apply only to the specific lot and buffer that were tested.
Identity and purity are usually established with reversed-phase high-performance liquid chromatography combined with mass spectrometry. A gradient of water and acetonitrile containing trifluoroacetic acid is a common mobile phase, and ultraviolet detection near 214 nanometres responds to the peptide backbone. Mass spectrometry confirms the expected molecular mass and helps reveal truncation or oxidation products. Purity is reported as a peak-area percentage, a figure that depends on the wavelength and gradient used, so values from different laboratories are not always directly comparable. Peptide mapping and amino acid analysis provide additional confirmation when required.
Evidence outside the studied population is sparse. Trials have concentrated on premenopausal women with a defined diagnosis, and data for postmenopausal women, men, and people taking interacting medications remain limited. Non-prescription use of the peptide for comparable goals is widespread but is not supported by published controlled data. Observed changes in blood pressure have drawn attention to cardiovascular monitoring during use. The literature generally frames the compound as a targeted receptor agonist rather than a general libido enhancer, and basic questions about mechanism and long-term safety are unresolved.
Bremelanotide functions as an agonist at several melanocortin receptor subtypes, with the strongest functional activity reported at the MC4 subtype. MC4 receptors sit in hypothalamic circuits that influence appetite, energy balance, and components of sexual behaviour. Rodents lacking functional MC4 receptors show altered mating behaviour, which supports a role for this pathway in desire. The precise sequence of events connecting receptor activation to reported human effects remains only partly characterised. Because the same receptor family governs pigmentation and inflammatory signalling, selectivity is a recurring theme in pharmacological discussion.
The Stuart Patton Auditorium in the Agricultural Sciences and Industries Building at Penn State is dedicated in his honor “for his inquisitive nature and skill in imparting knowledge; for his enthusiasm for science and uncompromising respect for peers.” In 2018, Dr. Patton's colleague, Ian H. Mather, added this touching tribute to Patton in his article in the Journal of Dairy Science: "This review is dedicated to the memory of Stuart Patton (1920–2017), Evan Pugh Professor Emeritus, Pennsylvania State University, and colleague, friend, and unofficial mentor of the senior author (IHM). The footprints of Dr. Patton’s research are evident throughout the pages of this review" (article is Symposium Review: Intravital imaging of the lactating mammary gland in live mice reveals novel aspects of milk-lipid secretion In a letter submitted in support of Patton's nomination as a fellow of the American Dairy Science Association in 2001, Dr. Ian Maher stated the following, "Dr. Patton's research is characterized by careful attention to experimental detail and a thorough knowledge of the literature. The discussion sections of his papers are always brimming with ideas, thought provoking and creative. A consistent feature of the work is novelty, whether it is a simple solution to a practical problem, or an inspirational idea that leads to new avenues of research. An example of the former is the simple but elegant method Dr. Patton devised to separate milk-fat globules from skim-milk components in a single step by density gradient centrifugation (Patton, S., and Huston, G.E.
After 30 days, photosynthetic efficiency dropped by 85% in UV-exposed samples and 46% in non-UV-exposed samples. However, within 24 hours of returning to Earth-like conditions, photosynthesis began recovering, demonstrating X. parietina's ability to repair its photosynthetic system after prolonged extreme exposure. Recovery appears to be linked to antioxidant production. Under Mars-like conditions, oxidative stress increased antioxidant levels, protecting against UV and temperature fluctuations. Over 30 days, antioxidant levels declined as the lichen neutralized reactive oxygen species (ROS), indicating an adaptive response that supports survival in extreme environments. X. parietina minimizes metabolism under extreme conditions. In the Mars simulation study, photosystem II efficiency declined under UV stress but remained active. UV-shielded samples performed better, suggesting that without radiation exposure, X. parietina could survive Mars-like cold and low pressure. Raman spectroscopy revealed carotenoid and parietin degradation after prolonged UV exposure, but enough pigment remained to protect vital cells, leaving the lichen's structure intact.
Besides hemorrhagic stroke, myocardial infarction, coronary vasospasm, and sudden death have also rarely been reported with sympathomimetic ephedra compounds like pseudoephedrine and ephedrine. A 2005 meta-analysis found that pseudoephedrine at recommended doses had no meaningful effect on systolic or diastolic blood pressure in healthy individuals or people with controlled hypertension. Systolic blood pressure was found to slightly increase by 0.99 mm Hg on average and heart rate was found to slightly increase by 2.83 bpm on average. Conversely, there was no significant influence on diastolic blood pressure, which increased by 0.63 mg Hg. In people with controlled hypertension, systolic hypertension increased by a similar degree of 1.20 mm Hg. Immediate-release preparations, higher doses, being male, and shorter duration of use were all associated with greater cardiovascular effects. A small subset of individuals with autonomic instability, perhaps in turn resulting in greater adrenergic receptor sensitivity, may be substantially more sensitive to the cardiovascular effects of sympathomimetics. Subsequent to the 2005 meta-analysis, a 2015 systematic review and a 2018 meta-analysis found that pseudoephedrine at high doses (>170 mg) could increase heart rate and physical performance with larger effect sizes than lower doses. A 2007 Cochrane review assessed the side effects of short-term use of pseudoephedrine at recommended doses as a nasal decongestant.
Sources: en.wikipedia.org
In Canada there had been no requirement to be circumspect when addressing the egalitarian New Zealander Rutherford, but many people in Germany found his manner off-putting, and characterised him as an "Anglicised Berliner". Hahn completed his habilitation in early 1907, and became a Privatdozent. A thesis was not required; the Chemical Institute accepted one of his publications on radioactivity instead. Most of the organic chemists at the Chemical Institute did not regard Hahn's work as real chemistry. Fischer objected to Hahn's contention in his habilitation colloquium that many radioactive substances existed in such tiny amounts that they could only be detected by their radioactivity, venturing that he had always been able to detect substances with his keen sense of smell, but soon gave in. One department head remarked: "it is incredible what one gets to be a Privatdozent these days!"
== Risk of injury == Injuries can happen in activities like yoga and aerobics . Quick, ballistic stretching can cause injury if it is done incorrectly. If a bone, muscle, or any other part is stretched more than its capacity, it may lead to dislocation or muscle pulls. Overstretching can increase chances of injury by stretching the muscle too much. Overstretching could lead to a sprain or strain, which requires rest or even physical therapy to recover from.
McLeod syndrome ( mə-KLOWD) is an X-linked recessive genetic disorder that may affect the blood, brain, peripheral nerves, muscle, and heart. It is caused by a variety of recessively inherited mutations in the XK gene on the X chromosome. The gene is responsible for producing the Kx protein, a secondary supportive protein for the Kell antigen on the red blood cell surface.
==== Gateway theory ==== An association has been found between adolescent exposure to nicotine by smoking conventional cigarettes and the subsequent onset of using other dependence-producing substances. Strong temporal and dose-dependent associations have been reported, and a plausible biological mechanism (via rodent and human modeling) suggests that long-term changes in the neural reward system take place as a result of adolescent smoking. Adolescent smokers of conventional cigarettes have disproportionately high rates of comorbid substance use, and longitudinal studies have suggested that early adolescent smoking may be a starting point or "gateway" for substance use later in life, with this effect more likely for persons with attention deficit hyperactivity disorder (ADHD). Although factors such as genetic comorbidity, innate propensity for risk-taking, and social influences may underlie these findings, both human neuroimaging and animal studies suggest a neurobiological mechanism also plays a role. In addition, behavioral studies in adolescent and young adult smokers have revealed an increased propensity for risk-taking, both generally and in the presence of peers, and neuroimaging studies have shown altered frontal neural activation during a risk-taking task as compared with nonsmokers.
Sources: en.wikipedia.org
PT-141 was the internal development code assigned to bremelanotide during preclinical research. Reference sources sometimes index the peptide under the code rather than the generic name. The two terms describe the same molecule.
They are related but distinct cyclic peptides. Melanotan II is an earlier and less selective melanocortin analog. Bremelanotide was developed later with a narrower receptor profile and a defined clinical application.
The reviewed product is given by subcutaneous injection using a single-use autoinjector. Administration occurs under prescription supervision. The device delivers one fixed amount per use rather than a measured or adjustable quantity.
PT-141 is the research code for bremelanotide, a cyclic peptide developed as a melanocortin receptor agonist. The code has appeared in literature and catalog listings since early development. Bremelanotide is the international nonproprietary name.